Monopar Therapeutics, Inc.
(NASDAQ : MNPR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 0.73%245.291.5%$944.07m
MRNAModerna, Inc. -0.69%141.210.0%$800.32m
REGNRegeneron Pharmaceuticals, Inc. 0.82%599.322.6%$516.26m
VRTXVertex Pharmaceuticals, Inc. 1.48%280.251.9%$509.19m
GILDGilead Sciences, Inc. 0.02%62.221.0%$507.83m
NVAXNovavax, Inc. -0.16%50.9875.7%$416.48m
ILMNIllumina, Inc. -1.21%185.173.3%$353.22m
BIIBBiogen, Inc. 0.83%204.191.8%$244.19m
SNSSSunesis Pharmaceuticals, Inc. 3.59%3.460.7%$241.87m
CRSPCRISPR Therapeutics AG -0.84%62.750.6%$168.47m
BNTXBioNTech SE 0.90%141.080.0%$168.39m
BMRNBioMarin Pharmaceutical, Inc. 0.08%83.224.2%$123.62m
EXASEXACT Sciences Corp. -1.61%40.4517.7%$97.90m
IOVAIovance Biotherapeutics, Inc. -3.01%10.650.0%$92.77m
TECHBio-Techne Corp. -0.61%343.904.5%$92.65m

Company Profile

Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline includes Validive, Camsirubicin and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.